Halozyme Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | $28.0M | $43.0M | $43.3M |
| FY2016 | $199.2M | $-32.5M | $66.8M |
| FY2017 | $125.1M | $208.4M | $168.7M |
| FY2018 | $34.9M | $248.9M | $57.9M |
| FY2019 | $383.0M | $91.8M | $120.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | $28.0M | $43.0M | $43.3M |
| FY2016 | $199.2M | $-32.5M | $66.8M |
| FY2017 | $125.1M | $208.4M | $168.7M |
| FY2018 | $34.9M | $248.9M | $57.9M |
| FY2019 | $383.0M | $91.8M | $120.2M |